Lymphoma Clinical Trials

Showing 1981-2000 of 2,926 trials

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02538926

This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride with asparaginase work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Asparaginase breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. Giving combination chemotherapy with asparaginase may work better in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.

B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaRecurrent Adult Acute Lymphoblastic Leukemia+6 more

University of WashingtonStarted Jul 2018

Seattle, Washington, United States

COMPLETEDPhase 2

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00003311

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy in treating patients with newly diagnosed mantle cell lymphoma.

Lymphoma

M.D. Anderson Cancer Center19 participantsStarted May 1998

Houston, Texas, United States

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Related Searches

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

A Study of Enzastaurin in Participants With Follicular Lymphoma

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?

PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

A Multi-center, Prospective, Single-blind, Controlled Trial Comparing Diagnostic Value of Different EUS-FNA Techniques